Macular Degeneration is a medical condition that may result in blurred or no vision in the center of the visual field. There may be no symptoms at times at the beginning of macular degeneration, but eventually some people experience a gradual worsening of vision that may affect both or one eye.
MARKET DYNAMICS
The Macular Degeneration Treatment Market is anticipated to grow in the forecast period owing to driving factors such as increasing population of geriatric patients, rising patient population suffering from Macular Degeneration, growing awareness about drugs for treating AMD, introduction on new therapies, improving healthcare as well as healthcare infrastructure, and increase in prevalence and incidence of retinal disorders. Nevertheless, continuous pressure from some key players in binding the usage of different drugs for wet AMD and intrusive administration methods is expected to restrict the market growth during the forecast period.
MARKET SCOPE
The "Global Macular Degeneration Treatment Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Macular Degeneration Treatment Market with detailed market segmentation by Disease Indication, Drug Class, End User and geography. The global Macular Degeneration Treatment Market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Macular Degeneration Treatment Market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global Macular Degeneration Treatment Market is segmented on the basis of Disease Indication, Drug Class and End User. Based on Disease Indication the market is segmented into Dry Age-related macular degeneration treatment, Wet age-related macular de-generation treatment and Others. Based on Drug Class the market is segmented into Anti-Vascular endothelial growth factor and Others. Based on End User the market is segmented into Ambulatory Surgical Centers, Ophthalmic Clinics and Hospitals.
Get more information on this report :
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Macular Degeneration Treatment Market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Macular Degeneration Treatment Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Macular Degeneration Treatment Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Macular Degeneration Treatment Market in these regions.
Get more information on this report :
MARKET PLAYERS
The reports cover key developments in the Macular Degeneration Treatment Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Macular Degeneration Treatment Market are anticipated to lucrative growth opportunities in the future with the rising demand for Macular Degeneration Treatment Market in the global market. Below mentioned is the list of few companies engaged in the Macular Degeneration Treatment Market.
The report also includes the profiles of key Macular Degeneration Treatment Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development In Past Five Years.
GlaxoSmithKline plc
Novartis AG
Bayer AG
Neurotech Pharmaceuticals, Inc
Ophthotech Corporation
F. Hoffmann-La Roche Ltd
StemCells Inc
Pfizer, Inc
Sanofi
Santen Pharmaceuticals
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Get more information on this report :
TABLE OF CONTENTS
1. INTRODUCTION 1.1. SCOPE OF THE STUDY 1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE 1.3. MARKET SEGMENTATION 1.3.1 Macular Degeneration Treatment Market - By Disease Indication 1.3.2 Macular Degeneration Treatment Market - By Drug Class 1.3.3 Macular Degeneration Treatment Market - By End User 1.3.4 Macular Degeneration Treatment Market - By Region 1.3.4.1 By Country 2. KEY TAKEWAYS 3. RESEARCH METHODOLOGY 4. MACULAR DEGENERATION TREATMENT MARKET LANDSCAPE 4.1. OVERVIEW 4.2. PEST ANALYSIS 4.2.1 North America - Pest Analysis 4.2.2 Europe - Pest Analysis 4.2.3 Asia-Pacific - Pest Analysis 4.2.4 Middle East and Africa - Pest Analysis 4.2.5 South and Central America - Pest Analysis 4.3. EXPERT OPINIONS 5. MACULAR DEGENERATION TREATMENT MARKET - KEY MARKET DYNAMICS 5.1. KEY MARKET DRIVERS 5.2. KEY MARKET RESTRAINTS 5.3. KEY MARKET OPPORTUNITIES 5.4. FUTURE TRENDS 5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC 6. MACULAR DEGENERATION TREATMENT MARKET - GLOBAL MARKET ANALYSIS 6.1. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET OVERVIEW 6.2. MACULAR DEGENERATION TREATMENT - GLOBAL MARKET AND FORECAST TO 2028 6.3. MARKET POSITIONING/MARKET SHARE 7. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE INDICATION 7.1. OVERVIEW 7.2. DISEASE INDICATION MARKET FORECASTS AND ANALYSIS 7.3. DRY AGE-RELATED MACULAR DEGENERATION TREATMENT 7.3.1. Overview 7.3.2. Dry Age-related macular degeneration treatment Market Forecast and Analysis 7.4. WET AGE-RELATED MACULAR DE-GENERATION TREATMENT 7.4.1. Overview 7.4.2. Wet age-related macular de-generation treatment Market Forecast and Analysis 7.5. OTHERS 7.5.1. Overview 7.5.2. Others Market Forecast and Analysis 8. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS 8.1. OVERVIEW 8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS 8.3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR 8.3.1. Overview 8.3.2. Anti-Vascular endothelial growth factor Market Forecast and Analysis 8.4. OTHERS 8.4.1. Overview 8.4.2. Others Market Forecast and Analysis 9. MACULAR DEGENERATION TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - END USER 9.1. OVERVIEW 9.2. END USER MARKET FORECASTS AND ANALYSIS 9.3. AMBULATORY SURGICAL CENTERS 9.3.1. Overview 9.3.2. Ambulatory Surgical Centers Market Forecast and Analysis 9.4. OPHTHALMIC CLINICS 9.4.1. Overview 9.4.2. Ophthalmic Clinics Market Forecast and Analysis 9.5. HOSPITALS. 9.5.1. Overview 9.5.2. Hospitals. Market Forecast and Analysis 10. MACULAR DEGENERATION TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS 10.1. NORTH AMERICA 10.1.1 North America Macular Degeneration Treatment Market Overview 10.1.2 North America Macular Degeneration Treatment Market Forecasts and Analysis 10.1.3 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication 10.1.4 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class 10.1.5 North America Macular Degeneration Treatment Market Forecasts and Analysis - By End User 10.1.6 North America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries 10.1.6.1 United States Macular Degeneration Treatment Market 10.1.6.1.1 United States Macular Degeneration Treatment Market by Disease Indication 10.1.6.1.2 United States Macular Degeneration Treatment Market by Drug Class 10.1.6.1.3 United States Macular Degeneration Treatment Market by End User 10.1.6.2 Canada Macular Degeneration Treatment Market 10.1.6.2.1 Canada Macular Degeneration Treatment Market by Disease Indication 10.1.6.2.2 Canada Macular Degeneration Treatment Market by Drug Class 10.1.6.2.3 Canada Macular Degeneration Treatment Market by End User 10.1.6.3 Mexico Macular Degeneration Treatment Market 10.1.6.3.1 Mexico Macular Degeneration Treatment Market by Disease Indication 10.1.6.3.2 Mexico Macular Degeneration Treatment Market by Drug Class 10.1.6.3.3 Mexico Macular Degeneration Treatment Market by End User 10.1.6.4 US Macular Degeneration Treatment Market 10.1.6.4.1 US Macular Degeneration Treatment Market by Disease Indication 10.1.6.4.2 US Macular Degeneration Treatment Market by Drug Class 10.1.6.4.3 US Macular Degeneration Treatment Market by End User 10.2. EUROPE 10.2.1 Europe Macular Degeneration Treatment Market Overview 10.2.2 Europe Macular Degeneration Treatment Market Forecasts and Analysis 10.2.3 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication 10.2.4 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class 10.2.5 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By End User 10.2.6 Europe Macular Degeneration Treatment Market Forecasts and Analysis - By Countries 10.2.6.1 Germany Macular Degeneration Treatment Market 10.2.6.1.1 Germany Macular Degeneration Treatment Market by Disease Indication 10.2.6.1.2 Germany Macular Degeneration Treatment Market by Drug Class 10.2.6.1.3 Germany Macular Degeneration Treatment Market by End User 10.2.6.2 France Macular Degeneration Treatment Market 10.2.6.2.1 France Macular Degeneration Treatment Market by Disease Indication 10.2.6.2.2 France Macular Degeneration Treatment Market by Drug Class 10.2.6.2.3 France Macular Degeneration Treatment Market by End User 10.2.6.3 Italy Macular Degeneration Treatment Market 10.2.6.3.1 Italy Macular Degeneration Treatment Market by Disease Indication 10.2.6.3.2 Italy Macular Degeneration Treatment Market by Drug Class 10.2.6.3.3 Italy Macular Degeneration Treatment Market by End User 10.2.6.4 Spain Macular Degeneration Treatment Market 10.2.6.4.1 Spain Macular Degeneration Treatment Market by Disease Indication 10.2.6.4.2 Spain Macular Degeneration Treatment Market by Drug Class 10.2.6.4.3 Spain Macular Degeneration Treatment Market by End User 10.2.6.5 United Kingdom Macular Degeneration Treatment Market 10.2.6.5.1 United Kingdom Macular Degeneration Treatment Market by Disease Indication 10.2.6.5.2 United Kingdom Macular Degeneration Treatment Market by Drug Class 10.2.6.5.3 United Kingdom Macular Degeneration Treatment Market by End User 10.3. ASIA-PACIFIC 10.3.1 Asia-Pacific Macular Degeneration Treatment Market Overview 10.3.2 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis 10.3.3 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication 10.3.4 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class 10.3.5 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By End User 10.3.6 Asia-Pacific Macular Degeneration Treatment Market Forecasts and Analysis - By Countries 10.3.6.1 Australia Macular Degeneration Treatment Market 10.3.6.1.1 Australia Macular Degeneration Treatment Market by Disease Indication 10.3.6.1.2 Australia Macular Degeneration Treatment Market by Drug Class 10.3.6.1.3 Australia Macular Degeneration Treatment Market by End User 10.3.6.2 China Macular Degeneration Treatment Market 10.3.6.2.1 China Macular Degeneration Treatment Market by Disease Indication 10.3.6.2.2 China Macular Degeneration Treatment Market by Drug Class 10.3.6.2.3 China Macular Degeneration Treatment Market by End User 10.3.6.3 India Macular Degeneration Treatment Market 10.3.6.3.1 India Macular Degeneration Treatment Market by Disease Indication 10.3.6.3.2 India Macular Degeneration Treatment Market by Drug Class 10.3.6.3.3 India Macular Degeneration Treatment Market by End User 10.3.6.4 Japan Macular Degeneration Treatment Market 10.3.6.4.1 Japan Macular Degeneration Treatment Market by Disease Indication 10.3.6.4.2 Japan Macular Degeneration Treatment Market by Drug Class 10.3.6.4.3 Japan Macular Degeneration Treatment Market by End User 10.4. MIDDLE EAST AND AFRICA 10.4.1 Middle East and Africa Macular Degeneration Treatment Market Overview 10.4.2 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis 10.4.3 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication 10.4.4 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class 10.4.5 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By End User 10.4.6 Middle East and Africa Macular Degeneration Treatment Market Forecasts and Analysis - By Countries 10.4.6.1 South Africa Macular Degeneration Treatment Market 10.4.6.1.1 South Africa Macular Degeneration Treatment Market by Disease Indication 10.4.6.1.2 South Africa Macular Degeneration Treatment Market by Drug Class 10.4.6.1.3 South Africa Macular Degeneration Treatment Market by End User 10.4.6.2 Saudi Arabia Macular Degeneration Treatment Market 10.4.6.2.1 Saudi Arabia Macular Degeneration Treatment Market by Disease Indication 10.4.6.2.2 Saudi Arabia Macular Degeneration Treatment Market by Drug Class 10.4.6.2.3 Saudi Arabia Macular Degeneration Treatment Market by End User 10.4.6.3 U.A.E Macular Degeneration Treatment Market 10.4.6.3.1 U.A.E Macular Degeneration Treatment Market by Disease Indication 10.4.6.3.2 U.A.E Macular Degeneration Treatment Market by Drug Class 10.4.6.3.3 U.A.E Macular Degeneration Treatment Market by End User 10.5. SOUTH AND CENTRAL AMERICA 10.5.1 South and Central America Macular Degeneration Treatment Market Overview 10.5.2 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis 10.5.3 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Disease Indication 10.5.4 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Drug Class 10.5.5 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By End User 10.5.6 South and Central America Macular Degeneration Treatment Market Forecasts and Analysis - By Countries 10.5.6.1 Brazil Macular Degeneration Treatment Market 10.5.6.1.1 Brazil Macular Degeneration Treatment Market by Disease Indication 10.5.6.1.2 Brazil Macular Degeneration Treatment Market by Drug Class 10.5.6.1.3 Brazil Macular Degeneration Treatment Market by End User 10.5.6.2 Argentina Macular Degeneration Treatment Market 10.5.6.2.1 Argentina Macular Degeneration Treatment Market by Disease Indication 10.5.6.2.2 Argentina Macular Degeneration Treatment Market by Drug Class 10.5.6.2.3 Argentina Macular Degeneration Treatment Market by End User 11. INDUSTRY LANDSCAPE 11.1. MERGERS AND ACQUISITIONS 11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES 11.3. NEW PRODUCT LAUNCHES 11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS 12. MACULAR DEGENERATION TREATMENT MARKET, KEY COMPANY PROFILES 12.1. GLAXOSMITHKLINE PLC 12.1.1. Key Facts 12.1.2. Business Description 12.1.3. Products and Services 12.1.4. Financial Overview 12.1.5. SWOT Analysis 12.1.6. Key Developments 12.2. NOVARTIS AG 12.2.1. Key Facts 12.2.2. Business Description 12.2.3. Products and Services 12.2.4. Financial Overview 12.2.5. SWOT Analysis 12.2.6. Key Developments 12.3. BAYER AG 12.3.1. Key Facts 12.3.2. Business Description 12.3.3. Products and Services 12.3.4. Financial Overview 12.3.5. SWOT Analysis 12.3.6. Key Developments 12.4. NEUROTECH PHARMACEUTICALS, INC 12.4.1. Key Facts 12.4.2. Business Description 12.4.3. Products and Services 12.4.4. Financial Overview 12.4.5. SWOT Analysis 12.4.6. Key Developments 12.5. OPHTHOTECH CORPORATION 12.5.1. Key Facts 12.5.2. Business Description 12.5.3. Products and Services 12.5.4. Financial Overview 12.5.5. SWOT Analysis 12.5.6. Key Developments 12.6. F. HOFFMANN-LA ROCHE LTD 12.6.1. Key Facts 12.6.2. Business Description 12.6.3. Products and Services 12.6.4. Financial Overview 12.6.5. SWOT Analysis 12.6.6. Key Developments 12.7. STEMCELLS INC 12.7.1. Key Facts 12.7.2. Business Description 12.7.3. Products and Services 12.7.4. Financial Overview 12.7.5. SWOT Analysis 12.7.6. Key Developments 12.8. PFIZER, INC 12.8.1. Key Facts 12.8.2. Business Description 12.8.3. Products and Services 12.8.4. Financial Overview 12.8.5. SWOT Analysis 12.8.6. Key Developments 12.9. SANOFI 12.9.1. Key Facts 12.9.2. Business Description 12.9.3. Products and Services 12.9.4. Financial Overview 12.9.5. SWOT Analysis 12.9.6. Key Developments 12.10. SANTEN PHARMACEUTICALS 12.10.1. Key Facts 12.10.2. Business Description 12.10.3. Products and Services 12.10.4. Financial Overview 12.10.5. SWOT Analysis 12.10.6. Key Developments 13. APPENDIX 13.1. ABOUT THE INSIGHT PARTNERS 13.2. GLOSSARY OF TERMS
Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.